Endocrinol Metab.  2013 Jun;28(2):103-109. 10.3803/EnM.2013.28.2.103.

Hemoglobin A1c Is Positively Correlated with Framingham Risk Score in Older, Apparently Healthy Nondiabetic Korean Adults

• Shin JH
• Kang JI
• Jung Y
• Choi YM
• Park HJ
• So JH
• Kim JH
• Kim SY
• Bae HY

• KMID: 1973808
• DOI: http://doi.org/10.3803/EnM.2013.28.2.103

Abstract

BACKGROUND
Several studies have suggested that elevated levels of hemoglobin A1c (HbA1c) are associated with cardiovascular disease (CVD) in nondiabetic individuals. However, it is unclear whether HbA1c levels can serve as a simple screening marker for increased CVD risk in nondiabetic individuals. Our objective was to evaluate the relationship between HbA1c levels and CVD risk using the Framingham risk score (FRS) in older, apparently healthy nondiabetic Korean adults.
METHODS
We retrospectively studied 2,879 Korean adults between the ages of 40 and 79 who underwent voluntary health check-ups at the Health Promotion Center of our hospital from July 2009 to June 2011. Subjects were subdivided based on their HbA1c levels into four groups: tertiles within the HbA1c normal tolerance range and a group for subjects with an increased risk for diabetes (IRD).
RESULTS
The mean FRS for the upper tertile (9.6+/-3.8) group was significantly higher than that of the middle tertile (8.4+/-4.0) and lower tertile (7.6+/-3.8) groups. In addition, FRS was highest in the IRD group (10.5+/-3.7). Multiple linear regression analysis demonstrated that HbA1c levels exhibited a significant positive correlation with FRS when adjusted for confounding variables in all subjects (beta+/-standard error [SE], 0.018+/-0.002; R2, 0.131), women (beta+/-SE, 0.023+/-0.003; R2, 0.170), and men (beta+/-SE, 0.016+/-0.004; R2, 0.109).
CONCLUSION
HbA1c levels were positively correlated with FRS in older, apparently healthy nondiabetic Korean adults. We propose that HbA1c levels may reflect CVD risk in nondiabetic individuals.

Keyword

Hemoglobin A, glycosylated; Framingham risk score; Nondiabetic individuals

MeSH Terms

Adult
Cardiovascular Diseases
Confounding Factors (Epidemiology)
Female
Health Promotion
Hemoglobin A, Glycosylated
Hemoglobins
Humans
Linear Models
Male
Mass Screening
Retrospective Studies
Hemoglobin A, Glycosylated
Hemoglobins

Reference

1. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999. 22:233–240.

2. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 2004. 164:2147–2155.

3. Sarwar N, Aspelund T, Eiriksdottir G, Gobin R, Seshasai SR, Forouhi NG, Sigurdsson G, Danesh J, Gudnason V. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med. 2010. 7:e1000278.

4. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW. Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002. 25:1845–1850.

5. Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med. 2007. 167:1545–1551.

6. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med. 1984. 310:341–346.

7. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999. 42:926–931.

8. Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S. The Rancho Bernardo Study. GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes. Diabetes Care. 1996. 19:450–456.

9. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001. 322:15–18.

10. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010. 362:800–811.

11. Silbernagel G, Grammer TB, Winkelmann BR, Boehm BO, Marz W. Glycated hemoglobin predicts all-cause, cardiovascular, and cancer mortality in people without a history of diabetes undergoing coronary angiography. Diabetes Care. 2011. 34:1355–1361.

12. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med. 2005. 165:1910–1916.

13. Selvin E, Coresh J, Shahar E, Zhang L, Steffes M, Sharrett AR. Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Lancet Neurol. 2005. 4:821–826.

14. Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, Olofsson B, Pfeffer MA, Yusuf S. CHARM Program Investigators. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med. 2008. 168:1699–1704.

15. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002. 106:3143–3421.

16. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998. 97:1837–1847.

17. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991. 121(1 Pt 2):293–298.

18. Kang HM, Kim DJ. Metabolic syndrome versus Framingham risk score for association of self-reported coronary heart disease: the 2005 Korean Health and Nutrition Examination Survey. Diabetes Metab J. 2012. 36:237–244.

19. Ryoo JH, Cho SH, Kim SW. Prediction of risk factors for coronary heart disease using Framingham risk score in Korean men. PLoS One. 2012. 7:e45030.

20. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010. 33:Suppl 1. S62–S69.

21. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005. 28:2901–2907.

22. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993. 16:434–444.

23. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, Wong TY, McNeil J, Shaw JE. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007. 116:151–157.

24. Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes. 1994. 43:836–841.

25. Pani LN, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, Sullivan L, D'Agostino RB, Nathan DM. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care. 2008. 31:1991–1996.

26. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E. Diabetes Prevention Program Research Group. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care. 2007. 30:2453–2457.

27. Sung KC, Rhee EJ. Glycated haemoglobin as a predictor for metabolic syndrome in non-diabetic Korean adults. Diabet Med. 2007. 24:848–854.

28. Park SH, Yoon JS, Won KC, Lee HW. Usefulness of glycated hemoglobin as diagnostic criteria for metabolic syndrome. J Korean Med Sci. 2012. 27:1057–1061.